We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The National Diet and Nutrition Survey assesses the diet, nutrient intake and nutritional status of the general population of the UK.
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
Healthcare professionals prescribing montelukast should be alert to the risk of neuropsychiatric reactions in all patients including children and adolescents. Reported neuropsychiatric reactions include sleep disorders, hallucinations, anxiety and depression, as well as changes in behaviour and mood. Healthcare professionals...
Information for patients, healthcare professionals and developers of new medicines
How to use a crossover randomised controlled trial to evaluate your digital health product.
These reports explain our assessment of the scientific evidence used to lead to regulatory decisions on the safety of medicines or medicines classes.
How to comply with the requirements on promoting medicines to the public and to prescribers and suppliers of medicines.
The CMA investigated alleged excessive and unfair pricing, anti-competitive agreements and abusive conduct with respect to hydrocortisone tablets under Chapters I and II CA98 and Articles 101 and 102 TFEU.
A statement from the Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment (COC).
How to use an interrupted time series to evaluate your digital health product.
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
How the MHRA makes decisions on when a product is a medical device (borderline products), and which risk class should apply to a medical device.
These documents explain how OHID is approaching reduction and food and drink reformulation as part of the government’s obesity strategy.
Search for information about medicines including patient information leaflets (PILs), details on how the medicine can be used (SmPCs) and scientific reports (PARs).
A patient alert card is being introduced for men taking finasteride to help raise awareness of the risk of psychiatric side effects and sexual dysfunction, including the potential for sexual dysfunction to persist after treatment has stopped. Healthcare professionals are...
The MHRA will introduce a patient alert card to increase awareness among men taking finasteride about potential psychiatric and sexual side effects
Covering thalidomide, lenalidomide, and pomalidomide: temporary guidance for pregnancy prevention arrangements for patients taking them during COVID-19
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.